Literature DB >> 31954061

Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab.

E J Giamarellos-Bourboulis1, M Argyropoulou1, T Kanni1, T Spyridopoulos1, I Otto2, O Zenker2, R Guo2, N C Riedemann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31954061     DOI： 10.1111/bjd.18877

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  12 in total

1.  Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials.

Authors:  John W Frew
Journal:  J Am Acad Dermatol       Date:  2020-04-02       Impact factor: 11.527

2.  Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.

Authors:  Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew
Journal:  JAMA Dermatol       Date:  2022-03-01       Impact factor: 11.816

3.  Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.

Authors:  Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

Review 4.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

Review 5.  Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target.

Authors:  Chiara Agostinis; Andrea Balduit; Alessandro Mangogna; Gabriella Zito; Federico Romano; Giuseppe Ricci; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

Review 6.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

7.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 8.  Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.

Authors:  Pim Aarts; Koen Dudink; Allard R J V Vossen; Kelsey R van Straalen; Christine B Ardon; Errol P Prens; Hessel H van der Zee
Journal:  Drugs       Date:  2021-07-20       Impact factor: 9.546

Review 9.  Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis.

Authors:  Viktor A Zouboulis; Konstantin C Zouboulis; Christos C Zouboulis
Journal:  Pharmaceutics       Date:  2021-12-26       Impact factor: 6.321

10.  Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis.

Authors:  Johann E Gudjonsson; Lam C Tsoi; Feiyang Ma; Allison C Billi; K R van Straalen; A R J V Vossen; H H van der Zee; Paul W Harms; Rachael Wasikowski; Christine M Yee; Syed M Rizvi; Xianying Xing; Enze Xing; Olesya Plazyo; Chang Zeng; Matthew T Patrick; Margaret M Lowe; Richard E Burney; Jeffrey H Kozlow; Jill R Cherry-Bukowiec; Yanyun Jiang; Joseph Kirma; Stephan Weidinger; Kelly C Cushing; Michael D Rosenblum; Celine Berthier; Amanda S MacLeod; John J Voorhees; Fei Wen; J Michelle Kahlenberg; Emanual Maverakis; Robert L Modlin; Errol P Prens
Journal:  JCI Insight       Date:  2020-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.